DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01179347 (ClinicalTrials.gov)	September 2010	10/8/2010	Tiotropium Bromide in Cystic Fibrosis	A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.	Cystic Fibrosis	Drug: tiotropium Respimat® inhaler;Drug: Placebo Respimat® inhaler	Boehringer Ingelheim	NULL	Completed	N/A	N/A	All	464	Phase 3	United States;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01179347
(ClinicalTrials.gov)

September 2010

10/8/2010

Tiotropium Bromide in Cystic Fibrosis

A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.

Cystic Fibrosis

Drug: tiotropium Respimat® inhaler;Drug: Placebo Respimat® inhaler

Boehringer Ingelheim

NULL

Completed

N/A

All

464

Phase 3

United States;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom